FDA Clears Expanded Access IND for APT’s PhageBank™ Therapy to Combat COVID-19-related Bacterial Infections

November 18, 2020

Press Releases

Comments Off on FDA Clears Expanded Access IND for APT’s PhageBank™ Therapy to Combat COVID-19-related Bacterial Infections

A significant increase in mortality has been seen in COVID-19 patients with antibiotic resistant bacterial infections. APT has made available therapeutic phage treatment to physicians in the Rio Grande Valley of Texas who are treating COVID-19 patients with secondary Carbapenem Resistant Acinetobacter baumannii (CRAB) on an emergency basis Now the FDA has granted APT an Expanded […]

PhageBank™ Deployed in Texas Outbreak of Life-Threatening Carbapenem Resistant A. baumannii (CRAB) in COVID-19 Patients

November 2, 2020

Press Releases

Comments Off on PhageBank™ Deployed in Texas Outbreak of Life-Threatening Carbapenem Resistant A. baumannii (CRAB) in COVID-19 Patients

November 02, 2020 11:00 AM Eastern Standard Time Eight COVID-19 + CRAB patients have received PhageBank™ therapy under FDA-approved emergency allowance, with more anticipated Significant increased mortality has been observed from secondary CRAB infections in COVID-19 patients APT and its partners are currently self-funding emergency use of PhageBank™ in this patient group, and are seeking […]

Adaptive Phage Therapeutics Receives Orphan Drug Designation

October 29, 2020

News

Comments Off on Adaptive Phage Therapeutics Receives Orphan Drug Designation

Adaptive Phage Therapeutics (APT), announced the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for the treatment of prosthetic joint infections (PJI) utilizing PhageBank™.  Orphan drug designation is given to drugs and biologics being developed to treat rare medical conditions, specifically those affecting fewer than 200,000 persons in the U.S. Orphan […]

Adaptive Phage Therapeutics Receives Orphan Drug Designation for PhageBank™ in Prosthetic Joint Infections

October 22, 2020

Press Releases

Comments Off on Adaptive Phage Therapeutics Receives Orphan Drug Designation for PhageBank™ in Prosthetic Joint Infections

October 22, 2020 11:00 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of multi-drug resistant infectious diseases, today announced the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for the treatment of prosthetic joint infections […]

APT named 2020 Emerging Life Science Company of the Year

October 16, 2020

News

Comments Off on APT named 2020 Emerging Life Science Company of the Year

The Maryland Tech Council (MTC), Maryland’s largest technology and life sciences trade association, announced the winners of its 32nd Annual Industry Awards. Due to COVID-19, the association pivoted to a virtual live broadcast to announce winners for the first time in the organization’s history.

Adaptive Phage Therapeutics Receives Department of Defense Award for Development of COVID-19 Vaccine

August 20, 2020

Press Releases

Comments Off on Adaptive Phage Therapeutics Receives Department of Defense Award for Development of COVID-19 Vaccine

August 20, 2020 11:09 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of bacterial and viral infectious diseases, today announced the Department of Defense (DoD) awarded APT $9.8 million for research development of multiple high-priority, bacteriophage-based display vaccine candidates against the novel coronavirus […]

APT Receives DoD Award for Development of COVID-19 Vaccine

August 19, 2020

News

Comments Off on APT Receives DoD Award for Development of COVID-19 Vaccine

GAITHERSBURG, Md., August 19, 2020 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of bacterial and viral infectious diseases, today announced the Department of Defense (DoD) awarded APT $9.8 million for research development of multiple high-priority, bacteriophage-based display vaccine candidates against the novel coronavirus (SARS-CoV-2). The effort will advance and evaluate […]

Mayo Clinic as Lead Investor in Convertible Note Financing

August 5, 2020

News

Comments Off on Mayo Clinic as Lead Investor in Convertible Note Financing

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced Mayo Clinic has committed $1.75M as a lead investor in a $7 million convertible note financing round.

Adaptive Phage Therapeutics Announces Mayo Clinic as Lead Investor in Convertible Note Financing

August 5, 2020

Press Releases

Comments Off on Adaptive Phage Therapeutics Announces Mayo Clinic as Lead Investor in Convertible Note Financing

— Proceeds to fund clinical trial for PhageBank treatment in periprosthetic joint infections — August 05, 2020 09:00 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced Mayo Clinic has committed […]

APT featured in Netflix Series

August 2, 2020

News

Comments Off on APT featured in Netflix Series

APT is featured in episode 2 of the Netflix series Connected. Science journalist Latif Nasser investigates the surprising and intricate ways in which we are connected to each other, the world and the universe.